Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

O-004

Supelco

Oxymorphone solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C17H19NO4
CAS Number:
76-41-5
Molecular Weight:
301.34
MDL number:
MFCD00079194
UNSPSC Code:
41116107
PubChem Substance ID:
329818813
NACRES:
NA.24
Pricing and availability is not currently available.

grade

certified reference material

Quality Level

300

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal)

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

forensics and toxicology

format

single component solution

storage temp.

2-8°C

SMILES string

CN1CC[C@]23[C@H]4Oc5c(O)ccc(C[C@@H]1[C@]2(O)CCC4=O)c35

InChI

1S/C17H19NO4/c1-18-7-6-16-13-9-2-3-10(19)14(13)22-15(16)11(20)4-5-17(16,21)12(18)8-9/h2-3,12,15,19,21H,4-8H2,1H3/t12-,15+,16+,17-/m1/s1

InChI key

UQCNKQCJZOAFTQ-ISWURRPUSA-N

Gene Information

human ... OPRD1(4985) , OPRK1(4986) , OPRM1(4988)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

A certified Snap-N-Spike® solution of oxymorphone suitable for use in a variety of GC/MS or LC/MS applications from pain prescription monitoring, clinical toxicology, and pharmaceutical research to forensic analysis and urine drug testing. Oxymorphone, sold under trade names such as Opana®, Numorphan®, and Numorphone, is an opiate analgesic indicated for the relief of moderate to severe pain.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Numorphan is a registered trademark of Endo Pharmaceuticals Inc.
Opana is a registered trademark of Endo Pharmaceuticals Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

related product

Product No.
Description
Pricing

P-071

Pain Management Multi-component Opiate Mixture-13 solution, 100 μg/mL each component (10 μg/mL Fentanyl), ampule of 1.0 mL, certified reference material, Cerilliant®

H-098

6α/β-Hydroxyoxymorphone-D3 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-012

Noroxymorphone hydrochloride solution, 1.0 mg/mL in methanol: DMSO (80:20) (as free base), ampule of 1 mL, certified reference material, Cerilliant®

O-003

Oxymorphone-D3 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

O-019

Oxymorphone-D3 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

O-030

Oxymorphone-3-β-D-glucuronide solution, 100 μg/mL in methanol: water (1:1), ampule of 1 mL, certified reference material, Cerilliant®

O-031

Oxymorphone-D3-3-β-D-glucuronide solution, 100 μg/mL in methanol: water (1:1), ampule of 1 mL, certified reference material, Cerilliant®

O-004S

Oxymorphone solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Mark P Jensen et al.
The Clinical journal of pain, 29(4), 289-295 (2012-10-09)
To understand the factors that contribute to patient and physician global outcome ratings and the extent to which receiving different doses of opioids or placebo might influence the importance of these factors better. A secondary analysis was performed using data
Trine Naalsund Andreassen et al.
European journal of clinical pharmacology, 68(1), 55-64 (2011-07-08)
Opioids are recommended by the World Health Organization for moderate to severe cancer pain. Oxycodone is one of the most commonly used opioids and is metabolized in the liver by CYP3A4 and CYP2D6 enzymes. The aim of this cross-sectional study
Marco Pappagallo et al.
Postgraduate medicine, 124(5), 101-109 (2012-10-26)
Because rates of both opioid prescribing and opioid abuse have increased, drug companies have responded by considering strategies to make opioid formulations less attractive for abuse without compromising safety or efficacy for patients with legitimate pain management needs. The emergence
MMWR. Morbidity and mortality weekly report, 62(1), 1-4 (2013-01-11)
On August 13, 2012, a nephrologist reported to the Tennessee Department of Health (TDH) three cases of unexplained thrombotic thrombocytopenic purpura (TTP), a rare but serious blood disorder characterized by microangiopathic hemolytic anemia and thrombocytopenia. The annual incidence is approximately
Mark P Jensen et al.
Pain, 154(4), 534-538 (2013-02-05)
Assay sensitivity remains a significant issue in pain clinical trials. One possible method for increasing assay sensitivity for detecting changes in pain intensity is to increase the reliability of pain intensity assessment by increasing the number of intensity ratings obtained
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service